[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630701":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":24,"responsibleParty":52,"collaborators":56,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":10,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":80,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Sahlgrenska University Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Cohort A",null,"Intermediate-high risk pulmonary embolism - prospective phenotyping thorugh serial investigations day 0, 1, 2 30 and 90.",{"label":13,"type":10,"description":14,"interventionNames":10},"Cohort B","All risk classes of pulmonary embolism - retrospective and prospective phenotyping at day 0, 90 (inclusion) and \\>12 months (Cohorts overlap since all patients in Cohort A are also part of Cohort B)",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Rickard Zeijlon, MD, PhD","CONTACT","+46313428884","rickard.zeijlon@vgregion.se",{"name":22,"role":18,"phone":23,"phoneExt":10,"email":10},"Mazdak Tavoly, MD, PhD","+46313421000",[25,38,47],{"facility":26,"status":27,"city":28,"state":29,"zip":10,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":10},"Sahlgrenska University Hospital\u002FMölndal","NOT_YET_RECRUITING","Gothenburg","Region Västra Götaland","Sweden","SE",{"type":33,"coordinates":34},"Point",[35,36],11.96679,57.70716,{"lat":36,"lon":35},{"facility":39,"status":40,"city":28,"state":29,"zip":10,"country":30,"countryCode":31,"cosmosGeoPoint":41,"geoPoint":43,"contacts":44},"Sahlgrenska University Hospital\u002FSahlgrenska","RECRUITING",{"type":33,"coordinates":42},[35,36],{"lat":36,"lon":35},[45],{"name":17,"role":18,"phone":46,"phoneExt":10,"email":20},"+46705821889",{"facility":48,"status":27,"city":28,"state":29,"zip":10,"country":30,"countryCode":31,"cosmosGeoPoint":49,"geoPoint":51,"contacts":10},"Sahlgrenska University Hospital\u002FÖstra",{"type":33,"coordinates":50},[35,36],{"lat":36,"lon":35},{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Rickard Zeijlon","Consultant in Internal Medicine, Clinical Postdoctoral Researcher and Principal Investigator",[57],{"name":58,"class":6},"Gothia Forum - Center for Clinical Trial","100630701","repeated-examinations-for-typing-pulmonary-embolism-100630701",false,"NCT07491094","Repeated Examinations for Typing Pulmonary Embolism","Repeated Examinations for Typing Pulmonary Embolism (RE-TyPE)","RE-TyPE","Inclusion Criteria:\n\n1. Adult patients (≥ 18 years old) who is diagnosed with, or followed as out-patients for, PE at Sahlgrenska University Hospital\n2. Written informed consent\n\nExclusion Criteria from Cohort A:\n\n1. Low risk, intermediate-low risk or high risk PE\\*\n2. \\>48 hours since arrival to hospital\n3. Expected inability to comply with the protocol (e.g. dementia)\n\nThere are no exclusion criteria from Cohort B. Patients in Cohort B who are not part of Cohort A may be included at diagnosis (day 0) or at follow-up (\\~day 90).\n\n\\*If biomarkers (and\u002For echocardiography) are not available in hemodynamically stable patients, RV\u002FLV-ratio \\>1 will be considered as preliminary intermediate-high risk. If biomarkers later fall out negative, the patient will be considered as intermediate-low risk and will be moved to Cohort B","ALL","18 Years",{"count":70,"type":71},400,"ESTIMATED","OBSERVATIONAL","PURPOSE\n\nThe two related purposes of the RE-TyPE study are:\n\n1. To improve understanding of the early clinical course of intermediate-high risk pulmonary embolism and its association with outcome and\n2. To establish a platform for longitudinal follow-up for all pulmonary embolism at Sahlgrenska University Hospital\n\nHYPOTHESES\n\n1. The dynamic pattern of change, evaluated thorough repeated measures of biomarkers, electrocardiography and echocardiography during the first 48 hours after pulmonary embolism, better predicts outcome than static measurements currently used to predict outcome\n2. Establishment of a platform for longitudinal follow-up will improve quality of care and outcome for patients with pulmonary embolism at Sahlgrenska University Hospital",[75,76,77,78,79],"Pulmonary Embolism (Diagnosis)","Pulmonary Embolism Acute","Pulmonary Embolism With Acute Cor Pulmonale","Pulmonary Embolism With Right Ventricle Enlargement","Pulmonary Embolism (PE)",[81,82,83,84,85,86,87,88,89,90],"Echocardiography","Point Of Care UltraSound (POCUS)","Electrocardiography (ECG)","Biomarkers\u002FBlood","Troponin I","NT-pro-BNP","Lactate","Prediction model","Clinical deterioration","Death","2026-04-02",{"date":93,"type":94},"2026-04-06","ACTUAL",{"date":96,"type":94},"2026-04-01",{"date":98,"type":71},"2032-01-01",{"name":5,"class":6},3]